LAVA Medtech Acquisition Corp. Class A Common Stock
LVAC
LVAC was delisted on the 10th of May, 2023.
49 hedge funds and large institutions have $94.6M invested in LAVA Medtech Acquisition Corp. Class A Common Stock in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 3 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
4% more funds holding
Funds holding: 47 → 49 (+2)
1% more capital invested
Capital invested by funds: $93.7M → $94.6M (+$876K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$3.7M |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$3.51M |
| 3 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
+$1.35M |
| 4 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$1.11M |
| 5 |
MTCM
Mint Tower Capital Management
Amsterdam,
Netherlands
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$3.98M |
| 2 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
-$3.74M |
| 3 |
Goldman Sachs
New York
|
-$2.56M |
| 4 |
JP Morgan Chase
New York
|
-$1.25M |
| 5 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$852K |
LVAC Hedge Fund Activity: Q3 2022 in Review
49 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in LAVA Medtech Acquisition Corp. Class A Common Stock (LVAC) for Q3 2022, worth a combined $94.6M — up 0.94% from $93.7M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new LVAC positions and 3 closed out — a net gain of 2 holders — while 11 added to existing stakes and 5 trimmed.
The largest buyer was Marshall Wace, adding an estimated $3.7M. The largest seller was Mangrove Partners, exiting entirely with an estimated $3.98M sold.
- 49 institutional investors held LAVA Medtech Acquisition Corp. Class A Common Stock (LVAC) as of Q3 2022, up from 47 in Q2 2022.
- Funds reported $94.6M of LAVA Medtech Acquisition Corp. Class A Common Stock stock for Q3 2022, up 0.94% quarter-over-quarter.
- 5 funds opened new LAVA Medtech Acquisition Corp. Class A Common Stock positions in Q3 2022 and 3 closed out, a net change of +2 holders.
- The largest LAVA Medtech Acquisition Corp. Class A Common Stock buyer in Q3 2022 was Marshall Wace, an estimated $3.7M added.
- The largest LAVA Medtech Acquisition Corp. Class A Common Stock seller in Q3 2022 was Mangrove Partners, an estimated $3.98M sold.
Based on aggregated 13F filings for Q3 2022.